Short answer
Protalix BioTherapeutics, Inc. (PLX) filed an 8-K current report with the SEC on May 21, 2026 reporting Item 7.01 (Regulation FD Disclosure). Corporate presentation posted May 21, 2026, providing investors updated company information.
Protalix BioTherapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Corporate presentation posted May 21, 2026, providing investors updated company information
- Exhibit 99.1 contains the substantive presentation and likely investor-relevant disclosures
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Protalix BioTherapeutics, Inc. 8-K filings
Get the next PLX 8-K as it lands
Follow PLX for push alerts, or ask the research agent what this filing means.